Abstract
Nonmetastatic castration-resistant prostate cancer (nmCRPC) presents a challenge to urologists as currently there are no Food and Drug Administration-approved therapies. However, there are new imaging modalities, including fluciclovine positron emission tomography-computed tomography and Ga-PSMA (prostate specific membrane antigent) positron emission tomography-computed tomography, which are improving accuracy of diagnosis. With improved imaging, we are better able to target therapy. Today there are 3 ongoing clinical trials studying second-generation antiandrogens in nmCRPC, which hold the promise of a new treatment paradigm. In this article, we will review the new imaging techniques and the rationale behind novel treatment modalities in nmCRPC.
Copyright © 2018 Elsevier Inc. All rights reserved.
MeSH terms
-
Adenocarcinoma / blood
-
Adenocarcinoma / diagnostic imaging*
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / secondary
-
Androgen Antagonists / therapeutic use
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Benzamides
-
Biomarkers, Tumor / blood
-
Bone Neoplasms / diagnostic imaging
-
Bone Neoplasms / prevention & control
-
Bone Neoplasms / secondary
-
Carboxylic Acids
-
Clinical Trials, Phase III as Topic
-
Cyclobutanes
-
Disease Management
-
Drug Resistance, Neoplasm
-
Humans
-
Kallikreins / blood
-
Male
-
Multicenter Studies as Topic
-
Nitriles
-
Orchiectomy
-
Phenylthiohydantoin / analogs & derivatives
-
Phenylthiohydantoin / therapeutic use
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / diagnostic imaging*
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / pathology
-
Pyrazoles / therapeutic use
-
Randomized Controlled Trials as Topic
Substances
-
Androgen Antagonists
-
Antineoplastic Agents, Hormonal
-
Benzamides
-
Biomarkers, Tumor
-
Carboxylic Acids
-
Cyclobutanes
-
Nitriles
-
Pyrazoles
-
darolutamide
-
Phenylthiohydantoin
-
fluciclovine F-18
-
enzalutamide
-
KLK3 protein, human
-
Kallikreins
-
Prostate-Specific Antigen